“This trial is about more than just hair loss - it’s about medical ethics, patient safety, and scientific progress. For decades, safer alternatives to finasteride have been ignored despite mounting risks. The recent WSJ article is just the latest warning! Telehealth companies continue to push these drugs while downplaying side effects. The real question is: why have only two FDA-approved drugs existed for hair loss in over 30 years? It’s time for change.”
“This trial is about more than just hair loss - it’s about medical ethics, patient safety, and scientific progress. For decades, safer alternatives to finasteride have been ignored despite mounting risks. The recent WSJ article is just the latest warning! Telehealth companies continue to push these drugs while downplaying side effects. The real question is: why have only two FDA-approved drugs existed for hair loss in over 30 years? It’s time for change.”